The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Engerix-B is also offered as a four-dose series for adults who are undergoing hemodialysis (kidney dialysis). The current recommended hepatitis B vaccine schedule for adults who have not previously ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

John­son & John­son’s bur­geon­ing de­pres­sion treat­ment Spra­va­to eclipsed $1 bil­lion in rev­enue in 2024 as the phar­ma’s neu­ro­science pipeline comes in­to view.

nasal spray bottle WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...